Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of polo-like kinase-I

被引:24
作者
Denkert, Carsten
Thoma, Andrea
Niesporek, Silvia
Weichert, Wilko
Koch, Ines
Noske, Aurelia
Schicktanz, Hanka
Burkhardt, Mick
Jung, Klaus
Dietel, Manfred
Kristiansen, Glen
机构
[1] Charite Univ Med Berlin, Inst Pathol, D-10117 Berlin, Germany
[2] Charite Hosp, Dept Urol, Berlin, Germany
关键词
COX-2; prostate carcinoma; PIN; atrophy; polo-like kinase;
D O I
10.1002/pros.20467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Cyclooxygenases (COX) as well as Polo-like kinases (PLK) are involved in proliferation and cell cycle regulation and have been suggested for preventive and therapeutic approaches in prostate carcinoma. METHODS. In this study, we studied expression and prognostic impact of COX-2 in invasive prostate carcinoma, prostatic intraepithelial neoplasia (PIN), atrophic glands, and normal prostatic glands, and investigated the association between COX-2 and PLK-1. RESULTS. We observed a positivity for COX-2 in 72.1% of PIN and in 44.7% of prostate carcinomas with an overexpression of COX-2 in prostate cancer and PIN compared to benign prostatic tissue (P < 0.0005). Furthermore, we observed a strong correlation between expression of PLK-1 and COX-2 (P < 0.0005). CONCLUSIONS. To our knowledge, this is the first report of a correlation between COX-2 and PLK-1 in a malignant tumor. COX-2 and PLK-1 may be interesting targets for new molecular therapies in prostate cancer.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 43 条
[1]   Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis [J].
Arai, T ;
Fujita, K ;
Fujime, M ;
Irimura, T .
INTERNATIONAL JOURNAL OF UROLOGY, 2005, 12 (07) :654-661
[2]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[3]   Polo-like kinases and centrosome regulation [J].
Dai, W ;
Wang, Q ;
Traganos, F .
ONCOGENE, 2002, 21 (40) :6195-6200
[4]   Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells [J].
Dandekar, DS ;
Lopez, M ;
Carey, RI ;
Lokeshwar, BL .
INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (03) :484-492
[5]   Inhibition of cyclooxygenase (COX)-2 expression by tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs [J].
Dandekar, DS ;
Lokeshwar, BL .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8037-8047
[6]   Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma [J].
Denkert, C ;
Köbel, M ;
Pest, S ;
Koch, I ;
Berger, S ;
Schwabe, M ;
Siegert, A ;
Reies, A ;
Klosterhalfen, B ;
Hauptmann, S .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (03) :893-903
[7]   Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma [J].
Denkert, C ;
Weichert, W ;
Winzer, KJ ;
Müller, BM ;
Noske, A ;
Niesporek, S ;
Kristiansen, G ;
Guski, H ;
Dietel, M ;
Hauptmann, S .
CLINICAL CANCER RESEARCH, 2004, 10 (16) :5580-5586
[8]  
Donaldson MM, 2001, J CELL SCI, V114, P2357
[9]   Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays [J].
Faith, DA ;
Isaacs, WB ;
Morgan, JD ;
Fedor, HL ;
Hicks, JL ;
Mangold, LA ;
Walsh, PC ;
Partin, AW ;
Platz, EA ;
Luo, J ;
De Marzo, AM .
PROSTATE, 2004, 61 (03) :215-227
[10]   Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome [J].
Foster, CS ;
Falconer, A ;
Dodson, AR ;
Norman, AR ;
Dennis, N ;
Fletcher, A ;
Southgate, C ;
Dowe, A ;
Dearnaley, D ;
Jhavar, S ;
Eeles, R ;
Feber, A ;
Cooper, CS .
ONCOGENE, 2004, 23 (35) :5871-5879